Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with stabilization of lung function, reduction in symptoms, and improvement in qualityof-life measures. Lymphangioleiomyomatosis (LAM) is an uncommon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine Jg. 364; H. 17; S. 1595 - 1606
Hauptverfasser:	McCormack, Francis X, Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G, Strange, Charlie, Nakata, Koh, Barker, Alan F, Chapman, Jeffrey T, Brantly, Mark L, Stocks, James M, Brown, Kevin K, Lynch, Joseph P, Goldberg, Hilary J, Young, Lisa R, Kinder, Brent W, Downey, Gregory P, Sullivan, Eugene J, Colby, Thomas V, McKay, Roy T, Cohen, Marsha M, Korbee, Leslie, Taveira-DaSilva, Angelo M, Lee, Hye-Seung, Krischer, Jeffrey P, Trapnell, Bruce C
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Massachusetts Medical Society 28.04.2011
Schlagworte:	Adult Double-Blind Method Female Forced Expiratory Volume - drug effects Human subjects Humans Intention to Treat Analysis Kinases Lungs Lymphangioleiomyomatosis - drug therapy Lymphangioleiomyomatosis - physiopathology Medication Adherence Middle Aged Observation Quality of Life Sirolimus - adverse effects Sirolimus - blood Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors Vascular endothelial growth factor Vital Capacity - drug effects Womens health
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!